DAFTAR PUSTAKA

1. Nursiah S. Pola Kuman Aerob Penyebab OMSK dan Kepekaan Terhadap Beberapa
Antibiotika di Bagian THT FK USU/RSUP. H. Adam Malik Medan. Medan : FK USU.
2003.
2. WHO. Chronic suppurative otitis media burden off illness and management options. Child
and Adolescent Health and Development Prevention of Blindness and Deafness. Geneva
Switzerland. 2004.
3. Chole RA, Nason R. Chronic otitis media and cholesteatoma. Dalam: Ballenger’s manual of
otorhinology head and neck surgery. Connecticut: BC Decker; 2009. p. 217-27.
4. Vikram BK, Khaja N, Udayashankar SG, Venkatesha BK, Manjurath D. Clinico-
epidemiological study of complicated and uncomplicated chronic suppurative otitis media.
The Journal of Laryngology & Otology 2008;122: 442-6.
5. Aboet A. Radang telinga tengah menahun. Pidato Pengukuhan Jabatan Guru Besar Tetap
Bidang Ilmu Kesehatan Telinga Hidung Tenggorok Bedah Kepala Leher. Medan: Fakultas
Kedokteran Universitas Sumatera Utara; 2007.
6. Gustomo BS. Gambaran otitis media supuratif kronis tipe bahaya di RSUD Dr. Moewardi
Surakarta tahun 2007-2009. Kumpulan Abstrak PITO-5 & AANOA-3. Yogyakarta:
PERHATI; 2010.
7. Monasta L, Ronfani L, Marchetti F, et al. Burden of disease caused by otitis media:
systematic review and global estimates. PLoS One. 2012;7(4):e36226.
8. Kennedy KL, Singh AK. Middle Ear, Cholesteatoma. 2017 Okt 6. Dalam: StatPearls
[Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-. Diakses dari:
https://www.ncbi.nlm.nih.gov/books/NBK448108/
9. Louw L. Acquired cholesteatoma pathogenesis: stepwise explanations. J Laryngol Otol.
2010;124(6):587–593.
10. da Costa S S, Teixeira A R, Rosito L P. The contralateral ear in cholesteatoma. Eur Arch
Otorhinolaryngol. 2016;273(7):1717–1721.
11. Kuo C L. Etiopathogenesis of acquired cholesteatoma: prominent theories and recent
advances in biomolecular research. Laryngoscope. 2015;125(1):234–240
12. Welkoborsky HJ. Current concepts of the pathogenesis of acquired middle ear
cholesteatoma. Laryngorhinootologie 2011;90: 38-48.
13. Caliman e Gurgel JD, Pereira SB, Alves AL, Ribeiro FQ. Hyperproliferation markers in ear
canal epidermis. Braz J Otorhinolaryngol 2010;76: 667-671.
14. Vitale RF, Pereira CS, Alves AL, Fregnani JH, Ribeiro FQ. TNF-R2 expression in acquired
middle ear cholesteatoma. Braz J Otorhinolaryngol 2011;77: 531-536.
15. Olszewska E, Chodynicki S. Immunological problems in middle ear cholesteatoma.
Otolaryngol Pol 2004;58: 85-90.
16. Juhn SK, Jung MK, Hoffman MD, Drew BR, Preciado DA, et al. The role of inflammatory
mediators in the pathogenesis of otitis media and sequelae. Clin Exp Otorhinolaryngol
2008;1: 117-138.
17. Vitale RF, Ribeiro Fde A. The role of tumor necrosis factor-alpha (TNF-alpha) in bone
resorption present in middle ear cholesteatoma. Braz J Otorhinolaryngol 2007;73: 117-121.
18. Dornelles C, Costa SS, Meurer L, Schweiger C. Some considerations about acquired adult
and pediatric cholesteatomas. Braz J Otorhinolaryngol 2005;71: 536-545.
19. Frickmann H, Zautner AE. Cholesteatoma – A Potential Consequence of Chronic Middle Ear
Inflammation. Otolaryngology 2012;S5:001.
20. Soepardi EA, Iskandar N, Bashiruddin J, Restuti RD. Buku Ajar Ilmu Kesehatan Telinga
Hidung Tenggorok Kepala & Leher. Edisi ke-6. Jakarta : Balai Penerbit FKUI; 2008
21. Post JC, Stoodley P, Hall-Stoodley L, Ehrlich GD. The role of biofilms in otolaryngologic
infections. Curr Opin Otolaryngol Head Neck Surg 2004;12: 185-190.
22. Macassey E, Dawes P.Biofilms and their role in otorhinolaryngological disease. J Laryngol
Otol 2008;122: 1273-1278.
23. Post JC, Hiller NL, Nistico L, Stoodley P, Ehrlich GD. The role of biofilms in
otolaryngologic infections: update 2007. Curr Opin Otolaryngol Head Neck Surg 2007;15:
347-351.
24. Chole RA, Faddis BT. Evidence for microbial biofilms in cholesteatomas. Arch Otolaryngol
Head Neck Surg 2002;128: 1129-1133.
25. Kariya S, Okano M, Zhao P. et al. Activation of NLRP3 inflammasome in human middle ear
cholesteatoma and chronic otitis media. Acta Otolaryngol. 2016;136(2):136–140.
26. Kumar V, Abbas A K, Aster J C. Robbins Basic Pathology. General pathology of infectious
diseases; Philadelphia, PA: Elsevier; 2013. pp. 309–326.
27. Kılıçkaya MM, Aynali G, Tuz M, Bagcı Ö. Is There A Systemıc Inflammatory Effect of
Cholesteatoma?. Int Arch Otorhinolaryngol. 2016;21(1):42-45.
28. Chang JH, McCluskey PJ dan Wakefield D. Toll-like receptors in ocular immunity and the
immunopathogenesis of inflammatory eye disease. The British journal of ophthalmology.
2006;90, 103–108.
29. Akira S dan Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4, 499–511.
30. Wu, M. et al. TREM-1 amplifies corneal inflammation after Pseudomonas aeruginosa
infection by modulating Toll-like receptor signaling and Th1/Th2-type immune responses.
Infect Immun. 79, 2709–2716 (2011).
31. Pier GB. Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator
of inflammation and target for effective immunity. International journal of medical
microbiology: IJMM. 2007;297, 277–295.
32. Sun Y, Karmakar M, dan Roy S. TLR4 and TLR5 on corneal macrophages regulate
Pseudomonas aeruginosa keratitis by signaling through MyD88-dependent and -
independent pathways. J Immunol. 2010;185, 4272–4283.
33. Si Y, et al. TLR4 drives the pathogenesis of acquired cholesteatoma by promoting local
inflammation and bone destruction. Sci. Rep. 2015;5, 16683.
34. Shrestha S, Kafle P. Intraoperative Findings during Canal Wall Down Mastoidectomy in
Children. J Nep Paedtr Soc 2011;31(3):184-187.
35. Henatsch D, Alsulami S, Duijvestijn AM, Cleutjens JP, Peutz-Kootstra CJ, Stokroos RJ.
Histopathological and Inflammatory Features of Chronically Discharging Open Mastoid
Cavities Secondary Analysis of a Randomized Clinical Trial. JAMA Otolaryngol Head Neck
Surg. 2018;144(3):211–217.
36. Elbary MEA, Nasr WF, Sorour SS. Platelet-Rich Plasma in Reconstruction of Posterior
Meatal Wall after Canal Wall Down Mastoidectomy. Int Arch Otorhinolaryngol.
2017;22(2):103-107.
37. Jothiramalingam SB, Kumar D, Kumar P, Sasindran V, Kumar N. Atticoantral disease—
revisited. Indian J Otolaryngol Head Neck Surg. 2007;59(3):203-206.
38. Schreml S, Szeimies RM, Prantl L, Landthaler M, Babilas P. Wound healing in the 21st
century. J Am Acad Dermatol. 2010;63(5):866-881.
39. Riedel K, Ryssel H, Koellensperger E, Germann G, Kremer T. Pathogenesis of chronic
wounds. Chirurg. 2008;79(6):526-534.
40. Restuti RD. Pengaruh deksametason terhadap proliferasi sel, kadar IL-α, dan TNF-α. ORLI
2014; 44(1): 11-17.
41. Loy AHC, Tan AL, Lu PKA. Microbiology of chronic suppurative otitis media in Singapore.
Sing Med J. 2002; 43(6):296-9.
42. Vandevyver S, Dejager L, Tuckermann J, Libert C. New Insights into the Anti-inflammatory
Mechanisms of Glucocorticoids: An Emerging Role for Glucocorticoid-Receptor-Mediated
Transactivation, Endocrinology, 2013;154(3):993–1007.
43. Dorscheid DR, Wojcik KR, Marroquin B, White SR. Apoptosis of airway epithelial cells
induced. Am J Respir Crit Care Med 2001; 164:1940-7.
44. Abreu AM, Oliveira DWD, Marinho SA, Lima NL, de Miranda JL, dan Verli FD. Effect of
Topical Application of Different Substances on Fibroplasia in Cutaneous Surgical Wounds.
Dermatology, 2012:282973.
45. Lopes-Rocha R, de Miranda JL, Lima NL, et al. Effect of topical propolis and
dexamethasone on the healing of oral surgical wounds. Wound Healing Southern
Africa. 2012;5(1):25–30.
46. Roland PS, et al. Topical ciprofloxacin/dexamethasone otic suspension is superior to
ofloxacin otic solution in the treatment of granulation tissue in children with acute otitis
media with otorrhea through tympanostomy tubes. Otolaryngology–Head and Neck Surgery
2004;130(6):736-739.
47. Oishi Y, Fu ZW, Ohnuki Y, Kato H, dan Noguchi T. Molecular basis of the alteration in skin
collagen metabolism in response to in vivo dexamethasone treatment: effects on the synthesis
of collagen type I and III, collagenase, and tissue inhibitors of metalloproteinases. British
Journal of Dermatology 20002;147(5):859–868.
48. Sobol SE, et al. Effect of Corticosteroid-Antibiotic Agents on Granulation Tissue in a Murine
Model. Arch Otolaryngol Head Neck Surg. 2005;131:330-335.
49. Lim W, Park C, Shim MK, Lee YH, Lee YM, Lee Y. Glucocorticoids suppress hypoxia-
induced COX-2 and hypoxia inducible factor-1α expression through the induction of
glucocorticoid-induced leucine zipper. Br J Pharmacol. 2014;171(3):735-45.
50. Hofman D, et al. Use of topical corticosteroids on chronic leg ulcers. Journal of Wound Care
2007;16(5):227-230.
51. Beule AG, et al. Effects of Topically Applied Dexamethasone on Mucosal Wound Healing
Using a Drug‐Releasing Stent. Laryngoscope 118:2073-2077.
52. Lee JH, Oh SH, Kim TH, Go YY, Song JJ. Anti-apoptotic effect of dexamethasone in an
ototoxicity model. Biomater Res. 2017;21:4.
53. Lemke LE, McGee DH, Prieskorn DM, et al. Safety of Ciprofloxacin and Dexamethasone in
the Guinea Pig Middle Ear. Arch Otolaryngol Head Neck Surg. 2009;135(6):575–580.